Molecular approaches to diagnosis and management of ovarian cancer.
The recent advances in the understanding of the pathogenesis of ovarian cancer have been helpful in addressing issues in diagnosis, prognosis and management. The study of ovarian tumours by novel techniques such as immunohistochemistry, fluorescent in situ hybridisation, comparative genomic hybridisation, polymerase chain reaction and new tumour markers have aided the evaluation and application of new concepts into clinical practice. The correlation of novel surrogate tumour specific features with response to treatment and outcome in patients has defined prognostic factors which may allow the future design of tailored therapy based on a molecular profile of the tumour. These have also been used to design new approaches to therapy such as antibody targeting and gene therapy. The delineation of roles of c-erbB2, c-fms and other novel receptor kinases in the pathogenesis of ovarian cancer has led initially to the development of anti-c-erbB2 monoclonal antibody therapy. The discovery of BRCA1 and BRCA2 genes will have an impact in the diagnosis and the prevention of familial ovarian cancer. The important role played by recessive genes such as p53 in cancer has raised the possibility of restoration of gene function by gene therapy. Although the pathological diagnosis of ovarian cancer is still confirmed principally on morphological features, addition of newer investigations will increasingly be useful in addressing difficult diagnostic problems. The increasingly rapid pace of discovery of genes important in disease, makes it imperative that the evaluation of their contribution in the pathogenesis of ovarian cancer is undertaken swiftly, thus improving the overall management of patients and their outcome.
Katso
R M
RM
ICRF Molecular Oncology Laboratories, John Radcliffe Hospital, Headington, Oxford, UK.
Manek
S
S
O'Byrne
K
K
Playford
M P
MP
Le Meuth
V
V
Ganesan
T S
TS
D014408:Biomarkers, Tumor / Q000032:analysis; D005260:Female; D005799:Genes, Dominant; D016147:Genes, Tumor Suppressor; D018815:Genes, erbB; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D009362:Neoplasm Metastasis; D009389:Neovascularization, Pathologic; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000473:pathology* / Q000628:therapy; D016133:Polymerase Chain Reaction; D011379:Prognosis; D011519:Proto-Oncogenes
D014408:Biomarkers, Tumor